Companies › Cellid
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Infectious disease, Vaccines; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AdCLD-CoV19-1 OMI Adenoviral vector-based COVID-19 vaccine (Omicron variant) | – | Phase 3 | COVID-19 | – |
| BVAC-E6E7 HPV E6/E7-targeting immunotherapeutic vaccine | E6, E7 | Phase 1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05993325 | AdCLD-CoV19-1 OMI | Phase 3 | COVID-19 | Vaccines | Mar 2025 |
| NCT06797986 | BVAC-E6E7 | Phase 1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Infectious disease | Mar 2027 |
Vaxcyte Dynavax Technologies Aribio Lab Guangzhou Patronus Biotech SK Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.